Clonidine 25 mcg tablets
Vasomotor symptoms (VMS) associated with menopause
Hormone replacement therapy (HRT) is the first-line treatment for menopausal VMS.
Where HRT is contraindicated or declined, a trial of Clonidine 25 mcg tablets may be considered for menopausal VMS.
Patients should be reviewed after 4 weeks and if no improvement in symptoms is observed or the patient is experiencing significant adverse events, treatment should be discontinued.
Reason for decision:
Suitable for initiation in primary care in line with restrictions